Hydroxyzine EQL Pharma
A new bioequivalence study has now been completed and approved by the authorities. This means that EQL Pharma, once again, can start selling its hydroxyzine products on both the Swedish and Danish market.In March 2017, the European Medicines Agency EMA recommended a temporary withdrawal of several drugs for which bioequivalence studies were conducted at Micro Therapeutic Research Labs. Among these were the drug Hydroxyzine EQL Pharma. "The authorities' approval is expected, but still good news. Our portfolio's still small and therefore the company is sensitive to disturbances in